{"id":"W2559885493","doi":"10.1200/jco.2011.29.7_suppl.117","title":"Phase III study of the efficacy and safety of zibotentan (ZD4054) in patients with bone metastatic castration-resistant prostate cancer (CRPC).","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Medicine; Clinical endpoint; Prostate cancer; Placebo; Internal medicine; Hazard ratio; Bone pain; Population; Bone metastasis; Cancer; Urology; Oncology; Confidence interval; Surgery; Randomized controlled trial; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00156405,0.001336717,0.002174952,0.0004717208,0.0005125477,0.0008347558,0.0009737956,0.001175428,0.004750265],"category_scores_gemma":[0.001001006,0.0006345003,0.001135782,0.0004800484,0.0008121529,0.0004948209,0.0003602765,0.002433018,0.0009279078],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001172856,"about_ca_system_score_gemma":0.002061184,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001855613,"about_ca_topic_score_gemma":0.002589669,"domain_scores_codex":[0.9995226,0.0002267481,0.00002424105,0.00005790532,0.00006476609,0.0001038099],"domain_scores_gemma":[0.9992788,0.0001172243,0.0001561096,0.00004537398,0.00005519741,0.0003473396],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8452247,0.05298157,0.006275039,0.0007296404,0.00155931,0.0002330848,0.000146638,0.0014809,0.03754592,0.0002662384,0.002747074,0.05080997],"study_design_scores_gemma":[0.7752228,0.2136621,0.007516264,0.00001440447,0.0002838652,0.0001037102,0.00002357909,0.0006198726,0.001487214,0.00006318161,0.0009903067,0.0000126611],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9879418,0.001902294,0.0008601131,0.0004728567,0.0001824724,0.005706235,0.001448303,0.0000975009,0.001388367],"genre_scores_gemma":[0.9848771,0.001504281,0.001809564,0.001096684,0.0001945162,0.00499772,0.003073754,0.00002561659,0.002420839],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004750265,"threshold_uncertainty_score":0.01589119,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1240587776185652,"score_gpt":0.4656068067404579,"score_spread":0.3415480291218927,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}